Table 1.
Risk classification system for IVDs.
Fig 1.
Number and type of diagnostics available for NTDs.
(A) RDT, Rapid diagnostic tests; EIA, enzyme immunoassay including chemiluminescence immunoanalysers; NAT, nucleic acid test including polymerase chain reaction and loop-mediated isothermal amplification. (B)The result includes diagnostics that are used for more than one disease (for example, microscopy tests for schistosomiasis and soil-transmitted helminths).
Table 2.
Number of diagnostics per purpose of diagnostics/intended use.
Table 3.
Number of diagnostics per purpose of diagnostic/intended use.
Table 4.
Risk classification.
Fig 2.
Estimated global need and market size for NTD diagnostics.
(A) Volume of diagnostics for yaws, lymphatic filariasis, soil transmitted helminthiasis, visceral leishmaniasis, Buruli ulcer and human African trypanosomiasis (HAT) is based on median procurement volume for 2017–2019. (B) Volume of diagnostics for schistosomiasis and onchocerciasis is based on WHO Preventive Chemotherapy Epidemiological Data Reporting Form reported from endemic countries from 2017–2019. (C) For Dengue, Chagas, cutaneous leishmaniasis, for which procurement volumes were not available, market size was estimated based on global disease prevalence. For Chagas disease, the estimated volume is for any type of diagnostic.